<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A glycine 185 to valine mutation of human P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (ABCB1, MDR1) has been previously isolated from high <z:chebi fb="0" ids="23359">colchicine</z:chebi> resistance cell lines </plain></SENT>
<SENT sid="1" pm="."><plain>We have employed purified and reconstituted P-<z:chebi fb="0" ids="17089">glycoproteins</z:chebi> expressed in Saccharomyces cerevisiae [Figler et al </plain></SENT>
<SENT sid="2" pm="."><plain>(2000) Arch </plain></SENT>
<SENT sid="3" pm="."><plain>Biochem </plain></SENT>
<SENT sid="4" pm="."><plain>Biophys </plain></SENT>
<SENT sid="5" pm="."><plain>376, 34-46] and devised a set of thermodynamic analyses to reveal the mechanism of improved resistance </plain></SENT>
<SENT sid="6" pm="."><plain>Purified G185V enzyme shows altered basal ATPase activity but a strong stimulation of <z:chebi fb="0" ids="23359">colchicine</z:chebi>- and <z:chebi fb="0" ids="4911">etoposide</z:chebi>-dependent activities, suggesting a tight regulation of ATPase activity by these drugs </plain></SENT>
<SENT sid="7" pm="."><plain>The mutant enzyme has a higher apparent K(m) for <z:chebi fb="0" ids="23359">colchicine</z:chebi> and a lower K(m) for <z:chebi fb="0" ids="4911">etoposide</z:chebi> than that of <z:mp ids='MP_0002169'>wild type</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Kinetic constants for other transported drugs were not significantly modified by this mutation </plain></SENT>
<SENT sid="9" pm="."><plain>Systematic thermodynamic analyses indicate that the G185V enzyme has modified thermodynamic properties of <z:chebi fb="0" ids="23359">colchicine</z:chebi>- and <z:chebi fb="0" ids="4911">etoposide</z:chebi>-dependent activities </plain></SENT>
<SENT sid="10" pm="."><plain>To improve the rate of <z:chebi fb="0" ids="23359">colchicine</z:chebi> or <z:chebi fb="0" ids="4911">etoposide</z:chebi> transport, the G185V enzyme has lowered the Arrhenius activation energy of the transport rate-limiting step </plain></SENT>
<SENT sid="11" pm="."><plain>The high transition state energies of <z:mp ids='MP_0002169'>wild-type</z:mp> P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi>, when transporting <z:chebi fb="0" ids="4911">etoposide</z:chebi> or <z:chebi fb="0" ids="23359">colchicine</z:chebi>, increase the probability of nonproductive degradation of the transition state without transport </plain></SENT>
<SENT sid="12" pm="."><plain>G185V P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> transports <z:chebi fb="0" ids="4911">etoposide</z:chebi> or <z:chebi fb="0" ids="23359">colchicine</z:chebi> in an energetically more efficient way with decreased enthalpic and entropic components of the activation energy </plain></SENT>
<SENT sid="13" pm="."><plain>Our new data fully reconcile the apparently conflicting results of previous studies </plain></SENT>
<SENT sid="14" pm="."><plain>EPR analysis of the spin-labeled G185C enzyme in a cysteine-less background and kinetic parameters of the G185C enzyme indicate that position 185 is surrounded by other residues and is volume sensitive </plain></SENT>
<SENT sid="15" pm="."><plain>These results and atomic detail structural modeling suggest that residue 185 is a pivotal point in transmitting conformational changes between the catalytic sites and the <z:chebi fb="0" ids="23359">colchicine</z:chebi> drug binding domain </plain></SENT>
<SENT sid="16" pm="."><plain>Replacement of this residue with a bulky valine alters this communication and results in more efficient transport of <z:chebi fb="0" ids="4911">etoposide</z:chebi> or <z:chebi fb="0" ids="23359">colchicine</z:chebi> </plain></SENT>
</text></document>